<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392520</url>
  </required_header>
  <id_info>
    <org_study_id>luteal antag OHSS RCT</org_study_id>
    <nct_id>NCT02392520</nct_id>
  </id_info>
  <brief_title>Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)</brief_title>
  <official_title>GnRH Antagonist in the Luteal Phase Compared to Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) in Whom All Embryos Are Cryopreserved</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eugonia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eugonia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare the novel method of GnRH antagonist administration in the luteal
      phase versus conventional treatment in IVF patients who develop severe early ovarian
      hyperstimulation syndrome and have all their embryos cryopreserved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GnRH antagonist administration in the luteal phase has been proposed as a strategy for the
      treatment of established severe early OHSS, causing rapid regression of the syndrome on an
      outpatient basis. The approach has been described as tertiary OHSS prevention, thereby
      complementing the primary prevention (GnRH antagonist protocol) and secondary prevention
      (GnRH agonist trigger) that constitute the OHSS-free clinic concept. No randomized controlled
      trials (RCT) exist to date comparing luteal GnRH antagonist administration versus
      conventional treatment.

      The aim of the present study is to compare the novel method of GnRH antagonist administration
      in the luteal phase versus conventional treatment with primary outcome time to severe OHSS
      regression, in IVF patients who develop severe early OHSS and have all their embryos
      cryopreserved.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to severe OHSS regression</measure>
    <time_frame>2- 21 days after severe OHSS diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for patient hospitalization</measure>
    <time_frame>2- 21 days after severe OHSS diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit levels</measure>
    <time_frame>8 days after severe early OHSS diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cells</measure>
    <time_frame>8 days after severe early OHSS diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter of ovaries</measure>
    <time_frame>8 days after severe early OHSS diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of ascites</measure>
    <time_frame>8 days after severe early OHSS diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol levels</measure>
    <time_frame>8 days after severe early OHSS diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progesterone levels</measure>
    <time_frame>8 days after severe early OHSS diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of vascular endothelial growth factor (VEGF)</measure>
    <time_frame>8 days after severe early OHSS diagnosis</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>Antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women with severe early OHSS will be treated with conventional treatment, such as intravenous albumin administration, paracentesis of ascitic fluid, either on an outpatient or inpatient basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetrorelix (cetrotide)</intervention_name>
    <description>0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis</description>
    <arm_group_label>Antagonist</arm_group_label>
    <other_name>GnRH antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume</description>
    <arm_group_label>Conventional</arm_group_label>
    <other_name>conventional treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with established severe early OHSS.

          -  Criteria for the diagnosis of severe OHSS require:

               -  the presence of moderate (or higher) ascites and at least two of the following:

                    -  enlarged ovaries (&gt;100 mm maximal diameter),

                    -  haematocrit (Ht) &gt;45%,

                    -  white blood cell count (WBC) &gt;15,000/mm3.

        Exclusion Criteria:

          -  Women not fulfilling the above criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George T Lainas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barts and The London NHS Trust (ART Unit)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George T Lainas, PhD</last_name>
    <phone>00447969111871</phone>
    <email>ggslns@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trifon G Lainas, PhD</last_name>
    <phone>00302107236333</phone>
    <email>tlainas@otenet.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eugonia Unit of Assisted Reproduction</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online. 2007 Oct;15(4):408-12.</citation>
    <PMID>17908403</PMID>
  </reference>
  <reference>
    <citation>Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Iliadis GS, Kolibianakis EM. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online. 2009 Jan;18(1):15-20.</citation>
    <PMID>19146764</PMID>
  </reference>
  <reference>
    <citation>Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Alexopoulou E, Kolibianakis EM. Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase. Reprod Biomed Online. 2009 Dec;19(6):789-95.</citation>
    <PMID>20031018</PMID>
  </reference>
  <reference>
    <citation>Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Tarlatzi TB, Tarlatzis BC, Lainas TG. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol. 2012 Aug 31;10:69. doi: 10.1186/1477-7827-10-69.</citation>
    <PMID>22938051</PMID>
  </reference>
  <reference>
    <citation>Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas TG, Tarlatzis BC. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Hum Reprod. 2013 Jul;28(7):1929-42. doi: 10.1093/humrep/det114. Epub 2013 Apr 26.</citation>
    <PMID>23624582</PMID>
  </reference>
  <reference>
    <citation>Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas TG, Tarlatzis BC. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome. BJOG. 2014 Jun;121(7):848-55. doi: 10.1111/1471-0528.12572. Epub 2014 Feb 12.</citation>
    <PMID>24621101</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>severe OHSS</keyword>
  <keyword>antagonist administration</keyword>
  <keyword>conventional treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

